|1.||Bidlack, J M: 2 articles (01/2000 - 01/2000)|
|2.||Küçukhüseyin, C: 1 article (01/2003)|
|3.||Vanderwolf, C H: 1 article (12/2001)|
|4.||Buckton, G: 1 article (12/2001)|
|5.||Zibrowski, E M: 1 article (12/2001)|
|6.||Neumeyer, J L: 1 article (01/2000)|
|7.||Cohen, D J: 1 article (01/2000)|
|8.||Mello, N K: 1 article (01/2000)|
|9.||Negus, S S: 1 article (01/2000)|
|10.||Zong, R: 1 article (01/2000)|
|1.||Substance-Related Disorders (Drug Abuse)
|2.||Opioid-Related Disorders (Opiate Addiction)
01/01/1974 - "A controlled study using cyclazocine in the treatment of narcotic addiction."
05/01/1968 - "Clinical studies of cyclazocine in the treatment of narcotic addiction."
10/01/1980 - "The use of cyclazocine, a narcotic antagonist in the treatment of opiate addiction, is reviewed. "
10/01/1980 - "Cyclazocine in the treatment of opiate addiction: a review with recommendations."
05/01/1974 - "High-dose cyclazocine therapy of opiate dependence."
05/01/1978 - "In order to characterize the discriminative stimulus properties of cyclazocine squirrel monkeys were trained to discriminate between intramuscular injections of 0.1 mg/kg of cyclazocine and drug vehicle in a discrete-trial avoidance paradigm in which a response on one of two levers would prevent or terminate the delivery of a mild electric shock to the tail. "
11/15/1977 - "A dose ratio comparison of the interaction between morphine and cyclazocine with naloxone in rhesus monkeys on the shock titration task."
10/01/1983 - "We compared the antinociception produced by brief intermittent foot shock (0.8-1.0 mA for 20 sec) and morphine by measuring the peak and duration of the effect, the consequences of spinalectomy and the sensitivity to antagonism by naloxone and d- and l-pentazocine and cyclazocine. "
01/01/1982 - "Morphine, ketocyclazocine, cyclazocine, and SKF-10,047 increased responding that was suppressed by electric shock, and these increases were antagonized by naltrexone and naloxone. "
|4.||Cocaine-Related Disorders (Cocaine Addiction)
09/11/1998 - "Although the mechanistic basis for the results are not entirely understood, the data suggest that (+/-)-cyclazocine should be considered as a potential treatment for cocaine dependence."
09/11/1998 - "Based on the evidence that opioid mechanisms modulate the reinforcing effects of cocaine, it has been suggested that cyclazocine be reconsidered for use in treating cocaine dependence. "
01/13/2000 - "This report concerns the synthesis and preliminary pharmacological evaluation of a novel series of kappa agonists related to the morphinan (-)-cyclorphan (3a) and the benzomorphan (-)-cyclazocine (2) as potential agents for the pharmacotherapy of cocaine abuse. "
|5.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
05/01/1988 - "In contrast, (d)-cyclazocine produced "psychotomimetic-like" effects, but no withdrawal symptoms. "
05/01/1988 - "(l)-Cyclazocine precipitated withdrawal symptoms in morphine-dependent rats. "
03/01/1971 - "The opiate-antagonist analgesics pentazocine, nalorphine and cyclazocine either had no effect on withdrawal symptoms or increased their severity.5. In morphine dependent rats under continued morphine administration subcutaneous doses of the opiate-antagonists nalorphine, cyclazocine and naloxone all precipitated the withdrawal symptoms of body weight loss and increased defaecation. "
|2.||Morphine (MS Contin)
|10.||delta Opioid Receptors (delta Opioid Receptor)
|3.||Drug Therapy (Chemotherapy)